Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE), 2025
ESPE-ESE 2025 10 - 13 May 2025

Weekly somapacitan is effective and well-tolerated in children with noonan syndrome: randomized phase 3 trial

Authors :

Alexander A. L. Jorge1; Assunta Albanese2; Michael Højby3; Kamil Soltysik3; Thomas Edouard4,5; Anna Grandone6; Michael Tansey7; Jun Mori8
Affiliations
View Details Hide Details
Keywords
Rare Endocrine Disorder
Congress poster
Somapacitan